Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to our new professor

13 September 2019

Congratulations to Kristijan Ramadan of the Oxford Institute for Radiation Oncology, who has been recognised with a full professorial title by the University of Oxford.

Kristijan Ramadan has been awarded the title of 'Professor of Molecular Medicine'.

Kristijan is important and influential members of our research community and we are delighted that he has received this title.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine

Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’.

Tiffany Ma wins the inaugural BACR Student Impact Award 2022

Cancer Research UK to invest £11 million into cancer science in Oxford

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Professor Sibson secures further MRC DPFS funding

Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.